News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 2200S

2200S 5.9 mg $99.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Western blot analysis of extracts from Jurkat cells, untreated (-) or etoposide-treated (25 μM, overnight; +), using Cleaved PARP (Asp214) (D64E10) XP® Rabbit mAb #5625 (upper) or total PARP Antibody #9542 (lower).

Learn more about how we got this image

Chemical structure of etoposide.

Learn more about how we got this image
Image

Product Usage Information

Etoposide is supplied as a lyophilized powder. For a 50 mM stock, reconstitute the 5.9 mg in 200 µl DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 5-50 µM for 4-24 hr. Soluble in DMSO at 100 mg/ml; very poorly soluble in ethanol and water with maximum solubility in water ~20-50 µM.


Storage: Store lyophilized or in solution at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

588.56 g/mol


Purity:

>99%


Molecular Formula:

C29H32O13


An anti-tumor agent that is commonly used as an apoptosis inducer, etoposide (VP-16) is a topoisomerase II inhibitor with an IC50 of 59.2 µM (1). Etoposide stabilizes a covalent topoisomerase II-cleaved DNA intermediate complex in the catalytic cycle of the enzyme, leading to genomic instability and cell death (2,3). This mechanism of action has been shown to delay progression of the cell cycle through the late S and early G2 phase (4,5).


1.  Terada, T. et al. (1993) J Med Chem 36, 1689-99.

2.  Baldwin, E.L. and Osheroff, N. (2005) Curr Med Chem Anticancer Agents 5, 363-72.

3.  Li, T.K. and Liu, L.F. (2001) Annu. Rev. Pharmacol. Toxicol. 41, 53-77.

4.  Dołega, A. (1998) Postepy Hig Med Dosw 52, 67-87.

5.  Smith, P.J. et al. (1994) Br J Cancer 70, 914-21.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.